

# Panel Survey of Ageing and the Elderly (PSAE) 2010

<https://neurodegenerationresearch.eu/survey/panel-survey-of-ageing-and-the-elderly-psae-2010/>

## Title of the cohort

Panel Survey of Ageing and the Elderly (PSAE) 2010

## Acronym for cohort

PSAE

## Name of Principal Investigator

Title          Prof

First name

Last name

## Address of institution where award is held

Institution

Street Address Box 720

City

Postcode          SE40530

## Country

- Sweden

## Website

<http://www.sociology.gu.se/english/?languageId=100001&contentId=-1&disableRedirect=true&returnUrl=http%3A%2F%2Fwww.sociology.gu.se%2F>

## Contact email

[bjorn.hallerod@sociology.gu.se](mailto:bjorn.hallerod@sociology.gu.se)

## Funding source

FAS

## 1. The cohort includes, or expects to include, incidence of the following conditions

- Neurodegenerative disease in general

## When studies on the above condition(s) are expected to become possible

- Already possible

## 2a. Stated aim of the cohort

Providing an overall broad picture of living conditions, general health, and economic conditions among older Swedes.

## **2b. Features distinguishing this cohort from other population cohorts**

It is not cohort study. It is a population based sample of the Swedish population 55 year of age or older. It is unique because of its breadth, because it facilitate comparisons with younger age group (the database includes a representative sample of the whole adult population), and because of it longitudinal design that makes it possible to trace part of the sample all the way back to 1979.

### **3a. i) Number of publications that involve use of cohort to date**

0

### **3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)**

### **3b. Publication list/link to where data or publications are accessible (if available)**

### **3c. Information (i.e. research findings) expected to be gained from the population cohort**

### **4a. Study criteria: age range of participants at recruitment**

Age in years from: They were aged 55-99 in 2002/2003. Part of the sample were interviewed in 1979, 1986/87 and 1996/99. We are currently, in 2011 and 2012, collecting new data. We are following the respondents to death and we are also continuously renew our sample in order to maintain a representative sample of the Swedish population.

To ('until death' if applicable):

### **4b. Study criteria: inclusion criteria**

Living in Sweden

### **4c. Study criteria: exclusion criteria**

Death or emigration

## **5. Size of the cohort (i.e. number of participants enrolled)**

- 5,001 – 10,000 participants

## **6a. Measures used to characterise participants**

No characteristics are used, it is a representative sample.

## **6b. Additional measures for participants with a clinical disorder**

No

## **6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

- No

## **7. Study design**

- Longitudinal

## **8. Cases matched by**

- Other health assessment (specify) / N/A
- No matching

## **9a. Does the study include a specialised subset of control participants**

- No

## **9b. If yes, description of specialised subset of control participants**

### **10a. i) Data collection start date**

01-01-1979

### **10a. ii) Data collection end date**

31-12-2012

### **10a iii) Data collection for this study is**

- Data collection ongoing
- Data analysis ongoing

## **10b. Plans to continue the cohort study beyond the current projected end date**

- Yes – intend to apply for funding

## **11. Data collected**

## **12. System in place to enable re-contact with patients for future studies**

- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

## **13a. Format and availability of data stored in a database**

Language used:

## **13b. Format and availability of data held as individual records**

Language used:

## **14a. Are data available to other groups**

Yes

## **14b. Access policy/mechanisms for access if data are available to other groups**

- Access independent of collaboration with PI
- National access

## **15. Data sharing policy specified as a condition of use**

- Data to be made publicly available immediately

**16a. Are tissues/samples/DNA available to other groups**

No

**16b. i) Description of available tissues/samples/DNA**

**16b. ii) Form available tissues/samples/DNA are supplied in**

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

**17. Is information on biological characteristics available to other groups**

- No